Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Company Information - Hendi Pharmaceutical is the developer of hydrochloride erlotinib, an EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] Group 2: Industry Context - Hydrochloride erlotinib can also be used for treating advanced non-small cell lung cancer patients who have failed previous chemotherapy [1]

Core Viewpoint - The company, Hendi Pharmaceutical (301211.SZ), has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Product Approval - The National Medical Products Administration has issued a marketing approval notice for hydrochloride erlotinib [1] - Hydrochloride erlotinib is classified as an EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] Group 2: Treatment Indications - Hydrochloride erlotinib can also be used for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]